Author

Yawen Wang

The University of Texas MD Anderson Cancer CenterORCID 0009-0001-6774-7948Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Yanyan HaniD· 2 shared Yonathan LissanuiD· 2 shared Hira MazhariD· 1 shared Ismail Mustafa MeraziD· 1 shared Jack A. RothiD· 1 shared Jing WangiD· 1 shared Kadir Caner AkdemiriD· 1 shared Manu M. SebastianiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Yanyan HanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.

Sasikumar Kotagiri, Yawen Wang, Yanyan Han, Xiaobing Liang, Nicholas Blazanin, Hira Mazhar, Manu M. Sebastian, Phuong Kieu Nguyen, Yongying Jiang, Yonathan Lissanu

This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.

Journal of Medicinal Chemistry · Apr 25, 2025Peer-reviewedCancer Biology

SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy

Yawen Wang, Ismail Mustafa Meraz, Md Qudratullah, Sasikumar Kotagiri, Yanyan Han, Yuanxin Xi, Jing Wang, Kadir Caner Akdemir, Jack A. Roth, Yonathan Lissanu

This study shows that SMARCA4 mutations in lung cancer disrupt enhancer landscapes and innate immune gene expression, leading to immunotherapy resistance.

Cancer Research · Mar 13, 2025Peer-reviewedImmunology